Schmidt-Ioanas M, Bender M, Roth A, Allewelt M, de Roux A, Lode H
Pneumologische Abteilung I, Helios Klinikum Emil von Behring, Lungenklinik Heckeshorn.
Dtsch Med Wochenschr. 2006 Mar 24;131(12):613-7. doi: 10.1055/s-2006-933703.
The definitive diagnosis of M. pneumoniae is encumbered by the lack of a rapid and cost-effective test of detection. The study aimed to determine if a single serological test within the first days of hospital admission may be relevant for the diagnosis of community-acquired pneumonia (CAP) caused by M. pneumoniae.
Patients with suspected of CAP were investigated for microbiological diagnosis based on respiratory samples (bronchoalveolar lavage, bronchial aspirate, sputum, throat rinse), blood culture and serology for detection of atypical organisms and viruses. Patients with M. pneumoniae antibody titers > or = 1:160 were further investigated by polymerase chain reaction (PCR) for detection of M. pneumoniae in respiratory samples. The group of CAP by M. pneumoniae (MP-CAP) included patients with serum titers > 1:160 of M. pneumoniae antibodies (based on a single antibody determination at admission). The control group (non-MP-CAP group) included patients with CAP by pathogens other than M. pneumoniae or with no definitive bacteriological diagnostic.
Twenty adults with MP-CAP and 20 controls with non-MP-CAP were included. PCR was positive in 18/20 (90 %) of the MP-CAP group and negative in the 9/9 (100 %) investigated patients of the non-MP-CAP group. The duration of symptoms prior to hospital admission was rather long in both groups (mean 13.2 days in the MP-CAP group and 12,7 days in the non-MP-CAP group). The MP-CAP group was significantly younger (p = 0.002), had subsequently less associated comorbidities (p < 0.001) and less purulent sputum (p = 0.003) than the non-MP-CAP group.
Single serology at admission with M. pneumoniae antibody titers > 1:160 may be useful for the diagnosis of CAP caused by M. pneumoniae in hospitalized patients with a long duration of symptoms (> 12 days).
由于缺乏快速且经济高效的检测方法,肺炎支原体的明确诊断受到阻碍。本研究旨在确定入院首日进行的单次血清学检测是否有助于诊断由肺炎支原体引起的社区获得性肺炎(CAP)。
对疑似CAP的患者进行基于呼吸道样本(支气管肺泡灌洗、支气管抽吸物、痰液、咽拭子)、血培养以及检测非典型病原体和病毒的血清学检查,以进行微生物学诊断。肺炎支原体抗体滴度≥1:160的患者进一步通过聚合酶链反应(PCR)检测呼吸道样本中的肺炎支原体。肺炎支原体所致CAP组(MP-CAP组)包括入院时血清滴度>1:160的肺炎支原体抗体患者(基于单次抗体检测)。对照组(非MP-CAP组)包括由肺炎支原体以外的病原体引起的CAP患者或无明确细菌学诊断的患者。
纳入20例MP-CAP成年患者和20例非MP-CAP对照患者。MP-CAP组20例中有18例(90%)PCR呈阳性,非MP-CAP组9例受检患者均为阴性(100%)。两组入院前症状持续时间均较长(MP-CAP组平均13.2天,非MP-CAP组平均12.7天)。与非MP-CAP组相比,MP-CAP组患者明显更年轻(p = 0.002),随后合并症更少(p<0.001),脓性痰液更少(p = 0.003)。
入院时单次血清学检测肺炎支原体抗体滴度>1:160,可能有助于诊断症状持续时间较长(>12天)的住院患者由肺炎支原体引起的CAP。